Daniel J Isaacman

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar)
    Daniel J Isaacman
    Global Medical Affairs, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA
    Vaccine 25:2420-7. 2007
  2. ncbi The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine
    Daniel J Isaacman
    Global Medical Affairs, Wyeth Pharmaceuticals, Collegeville, Pennsylvania, USA
    Clin Ther 30:341-57. 2008
  3. ncbi Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines
    Daniel J Isaacman
    Global Medical Affairs, Vaccines, Wyeth Pharmaceuticals Inc, Collegeville, PA, USA
    Int J Infect Dis 14:e197-209. 2010
  4. ncbi Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention
    Angela E Bridy-Pappas
    Wyeth Pharmaceuticals Inc, Global Medical Affairs, Collegeville, Pennsylvania, USA
    Pharmacotherapy 25:1193-212. 2005

Collaborators

Detail Information

Publications4

  1. ncbi Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar)
    Daniel J Isaacman
    Global Medical Affairs, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA
    Vaccine 25:2420-7. 2007
    ..Continued surveillance will be important, to follow future changes associated with non-vaccine type IPD, particularly among individuals with medical co-morbidities that may put them at higher risk of disease...
  2. ncbi The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine
    Daniel J Isaacman
    Global Medical Affairs, Wyeth Pharmaceuticals, Collegeville, Pennsylvania, USA
    Clin Ther 30:341-57. 2008
    ..Consideration of indirect protection against IPD may enhance cost-benefit evaluations of vaccination programs...
  3. ncbi Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines
    Daniel J Isaacman
    Global Medical Affairs, Vaccines, Wyeth Pharmaceuticals Inc, Collegeville, PA, USA
    Int J Infect Dis 14:e197-209. 2010
    ..The overall reported burden of invasive pneumococcal disease (IPD) varies among countries in Europe. This review describes the epidemiology and serotype distribution of IPD in European children from studies published from 1990 to 2008...
  4. ncbi Streptococcus pneumoniae: description of the pathogen, disease epidemiology, treatment, and prevention
    Angela E Bridy-Pappas
    Wyeth Pharmaceuticals Inc, Global Medical Affairs, Collegeville, Pennsylvania, USA
    Pharmacotherapy 25:1193-212. 2005
    ..Vaccines targeted at this pathogen are reviewed, and the clinical trials that evaluated their safety, efficacy, and effectiveness are summarized. Also provided are recommendations for use of these vaccines...